Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.

[1]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[2]  C. Patrono,et al.  Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. , 2012, Blood.

[3]  P. Hjemdahl,et al.  Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications , 2011, Thrombosis and Haemostasis.

[4]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[5]  Masafumi Ueno,et al.  Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease , 2011, Circulation. Cardiovascular interventions.

[6]  J. Dillinger,et al.  24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease , 2010, Thrombosis and Haemostasis.

[7]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[8]  T. Geisler,et al.  Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions , 2010, Clinical Research in Cardiology.

[9]  E. Grove,et al.  A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease , 2010, Thrombosis and Haemostasis.

[10]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[11]  V. Basevi.  Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[12]  E. Grove,et al.  The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease , 2009, Heart.

[13]  G. Tognoni,et al.  Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[14]  P. Macfarlane,et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[15]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[16]  K. Barber,et al.  Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients , 2008, Journal of Translational Medicine.

[17]  W Scott Beattie,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[18]  J. Turgeon,et al.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. , 2007, European heart journal.

[19]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[20]  C. Patrono,et al.  Drug Insight: aspirin resistance—fact or fashion? , 2007, Nature Clinical Practice Cardiovascular Medicine.

[21]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[22]  C. Pepine,et al.  Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. , 2006, Circulation.

[23]  P. Hjemdahl,et al.  Dose- and time-dependent antiplatelet effects of aspirin , 2006, Thrombosis and Haemostasis.

[24]  C. Macaya,et al.  Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. , 2006, The American journal of cardiology.

[25]  M. Quon,et al.  Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. , 2005, Journal of the American College of Cardiology.

[26]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[27]  A. Jacobs,et al.  Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.

[28]  Colin Mathers,et al.  The burden of mortality attributable to diabetes: realistic estimates for the year 2000. , 2005, Diabetes care.

[29]  杨靓,et al.  Aspirin resistance , 2004 .

[30]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[31]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[32]  D. Sane,et al.  Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance , 2002, Thrombosis and Haemostasis.

[33]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[34]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[35]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[36]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[37]  Y. Hong,et al.  Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  K. Grotemeyer,et al.  Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. , 1993, Thrombosis research.

[39]  A. Cerbone,et al.  Trial of repeated low-dose aspirin in diabetic angiopathy. , 1986, Blood.

[40]  G. Minno,et al.  Monitoring the entry of new platelets into the circulation after ingestion of aspirin. , 1983, Blood.